FDA regulations governing the format
and content of labeling for human prescription drug and biological
products requiring that the labeling of new and recently approved
products contain highlights of prescribing information, a table of
contents for prescribing information, reordering of certain
sections, minor content changes, and minimum graphical
requirements.
Statute at
Large: 52
Stat. 1040 Name of Statute: null
The changes in burden from the
information collection in the final rule are the result of
reductions in the number of submissions that have occurred because
6 years have expired under the implementation plan.
$210,000
No
No
No
No
No
Uncollected
Johnny Vilela 301 796-3792
juanmanuel.vilela@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.